The company estimates this will create several hundred more jobs, which they will begin filling this year.

The grand opening of the new facility, held on June 18th, hosted elected officials and leaders from the Danish political and life science community, including the Ministry of Taxation, the Japanese Ministry in Denmark, and the Mayor of Gladsaxe municipality.

 

The grand opening of the new facility, held on June 18th, hosted elected officials and leaders from the Danish political and life science community, including the Ministry of Taxation, the Japanese Ministry in Denmark, and the Mayor of Gladsaxe municipality. Photo: AGC Biologics

 

The expansion adds 19,000 m2 of space in a modern building that houses a large manufacturing floor, expanded quality control lab space, utilities to support all operations and prevent outages caused by natural disasters, and a fully dedicated warehouse to serve the entire AGC Biologics Copenhagen campus, the company states. The new manufacturing area offers 8 x 2,000 L single-use bioreactors with two seed trains, as well as two independent downstream suites – more than doubling the existing capacity offered at this site for mammalian-based projects.

One of the only sites in the world with multiple single-use bioreactor systems of this magnitude.”

AGC Biologics Copenhagen is now one of the only sites in the world with multiple single-use bioreactor systems of this magnitude capable of producing batches at high-levels of clinical and commercial production, it states.

 

AGC Biologics estimates this will create several hundred more jobs, which they will begin filling this year. Photo: AGC Biologics

 

“AGC Biologics Copenhagen site continues to be one of the most active in our network with all the necessary commercial approvals – FDA, EMA, HCA, PMDA, ANVISA etc. – and we are more than happy to offer the capacity and capabilities our current and future customers will look for with this completed expansion,” says Christoph Winterhalter, CBO, AGC Biologics.

The new AGC Biologics Copenhagen manufacturing building is planning production with its first customer, after completing this USD 200 million investment.

“I am extremely proud of the work and collaboration of everyone at our site over the last several years, it is truly remarkable to see what we can accomplish by working together. We are eager to offer more of the important capabilities the industry is looking for to support patients in need,” says Andrea C. Porchia, General Manager, AGC Biologics Copenhagen.

Photo: AGC Biologics